Latest Commercial Sales News

Li-S Energy’s lithium-sulfur battery powered the Pegasus drone through an almost two-hour Queensland flight covering more than 75 kilometres. The result strengthens the technology’s aviation credentials, but the partners are still assessing commercialisation rather than announcing sales.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.

Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.

Micro-X has secured an eight-month, US$0.75 million contract extension from the US Department of Homeland Security to upgrade its miniature CT baggage scanner for scaled manufacturing. The award advances a technology platform towards possible commercial use, but does not yet represent a product sale or customer deployment.

Lotus Resources delivered first uranium production from Kayelekera in more than a decade, but its first operating year brought a $100.1 million loss, heavy cash burn and an auditor-highlighted material uncertainty over its ability to continue as a going concern. The mine produced 332.1 thousand pounds of U3O8 before acid supply problems forced a temporary processing pause.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Zeotech Limited (ASX:ZEO) is moving Toondoon toward its first direct-shipping kaolin export after securing a potential A$200 million offtake agreement, while AusPozz™ and zeoteCH₄® produce encouraging trial results. The progress came alongside an A$8.15 million FY26 loss, negative operating cash flow and an acknowledgement that further funding may be required.

Waterco Limited (ASX:WAT) delivered record FY26 EBIT of $23.8 million and lifted net profit after tax 59.6% to $15.4 million, despite only modest revenue growth. The stronger result supports a higher fully franked dividend, but the group is carrying more debt and inventory as it expands manufacturing capacity.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

icetana AI has signed a five-year, $675,480 plus GST Antara Core contract with Millennium Services Group for deployment to one of Australia’s largest retail property groups. The deal is the third Antara Core sale in three months and is expected to add $135,096 to annual recurring revenue from 1 November 2026.

Li-S Energy says its Geelong lithium-sulfur production line is complete and has delivered 10Ah Power Cells to the US Army for testing. The company is targeting its first commercial battery sale in 2027, while holding A$15.6 million in cash and investments and A$9.3 million in secured grants yet to be received.

PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.